Although the sample size of IL-13-PE treated patients in TCGA was extremely small (n = 6), these preliminary results have significant implications and indicate that targeting of IL-13Rα2 in GBM treatment holds a promise, specifically for the IL-13Rα2 positive group of patients. The gene discussed is IL13RA2; the disease is glioblastoma.